Advertisement Positron acquires license to coronary disease program - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Positron acquires license to coronary disease program

Positron has acquired an exclusive license to a coronary disease reversal and prevention practice management program created by Lance Gould and the University of Texas Health Science Center at Houston.

Joe Oliverio, president of Positron, said: “We are grateful to the University of Texas Health Science Center at Houston and Dr Gould for selecting Positron as the exclusive licensee of their heart disease management product.

“The market is void of such a product and will position Positron to be able to offer a total cardiac solution to customers reaching well beyond the sale to physicians.”